Úspěšné použití rituximabu u pacienta s překrytím myelinové oligodendrocytové glykoproteinové encefalomyelitidy a systémového lupus erythematosus

Stáhnout PDF English version

Autoři: O. Kuryata ¹; V. V. Semenov ¹; T. Lysunets ²; V. Dubyna ³; O. Zhohalieva ⁴; V. Pashkovskyi ⁴
Působiště autorů: Department of Internal Medicine 2 and, Phthisiatry, Dnipro State Medical University, Dnipro, Ukraine ¹; Department of Rheumatology, Mechnikov, Dnipropetrovsk Regional Clinical, Hospital, Dnipro, Ukraine ²; Department of Anesthesiology and, Intensive Care #1, Mechnikov Dnipropetrovsk, Regional Clinical Hospital, Dnipro, Ukraine ³; Department of Neurology #1, Mechnikov, Dnipropetrovsk Regional Clinical, Hospital, Dnipro, Ukraine ⁴
Vyšlo v časopise: Cesk Slov Neurol N 2021; 84/117(4): 415-417
Kategorie: Dopisy redakci
doi: https://doi.org/10.48095/cccsnn2021415

Zdroje

1. Pröbstel AK, Thanei M, Erni B et al. Association of antibodies against myelin and neuronal antigens with neuroinflammation in systemic lupus erythematosus. Rheumatology 2019; 58 (5): 908–913. doi: 10.1093/rheumatology/key282.

2. Mader S, Jeganathan V, Arinuma Y et al. Understanding the antibody repertoire in neuropsychiatric systemic lupus erythematosus and neuromyelitis optica spectrum disorder: do they share common targets? Arthritis Rheumatol 2018; 70 (2): 277–286. doi: 10.1002/art.40 356.

3. Jarius S, Paul F, Aktas O et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation 2018; 15 (1): 134. doi: 10.1186/s12974-018-1144-2.

4. Wynford-Thomas R, Jacob A, Tomassini V. Neurological update: MOG antibody disease. J Neurol 2019; 266 (5): 1280–1286. doi: 10.1007/s00415-018-9122-2.

5. Ramanathan S, Mohammad S, Tantsis E et al. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry 2018; 89 (2): 127–137. doi: 10.1136/jnnp-2017-316880.

6. Fanouriakis A, Kostopoulou M, Alunno A et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 2019; 78 (6): 736–745. doi: 10.1136/annrheumdis-2019-215089.

7. Caroline Breis L, Schlindwein AM, Pastor Bandeira I et al. MOG-IgG-associated disorder and systemic lupus erythematosus disease: Systematic review. Lupus 2020; 30 (3): 385–392. doi: 10.1177/0961203320978514.

8. Filipov JJ, Zlatkov BK, Dimitrov EP. Plasma exchange in clinical practice. In: Tutar Y, Tutar L (eds). Plasma medicine – Concepts and clinical applications. [online]. Available from URL: http: //www.intechopen.com/books/plasma-medicine-concepts-and-clinical-applications/plasma-exchange-in-clinical-practice.

9. Guo Y, Tian X, Wang X et al. Adverse effects of immunoglobulin therapy. Front Immunol 2018; 9: 1299. doi: 10.3389/fimmu.2018.01299.

10. Jeffrey P. Callen MD. New warning issued for rituximab. [online]. Available from URL: https: //www.jwatch.org/JD200612220000001/2006/12/22/new-warning-issued-rituximab.